SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
GH

Guardant Health, Inc. (NASDAQ:GH)

US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
$145.83+$0.24 (+0.16%)
 
Market cap
$19.7B
Insider Score
Health Score
Analyst consensus
Listed since
Oct 4, 2018
Market Cap$19.73B+31.1%
Revenue (ttm)$1.28B+41.7%
Net Income-$485.07M-21.6%
EPS-$3.68-14.6%
Shares Out135.29M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,757,526
Open$143.10
Previous Close$145.59
Day's Range$141.00 - $148.26
52-Week Range$74.55 - $191.05
Beta1.66
AnalystsBuy
Price Target$203.40(+39.48%)
Earnings DateFeb 18, 2027

About GH

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

Address
3100 Hanover Street, Palo Alto, CA, 94304, US
Market Cap
19.73 billion
Employees
2,498
Industrial Classification
Medical - Diagnostics & Research

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$605.09K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
6 Buy0 Hold0 SellAvg target $177.14 (+21.7%)

6 firms rating GH in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From GH’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
+0.16%
5 Days
-2.49%
1 Month
-10.50%
6 Months
+22.60%
1 Year
+31.08%

Congress Trading

Recent trades of GH by members of U.S. Congress

Jonathan JacksonHouse / DPurchase$15.00K – $50.00KSep 28, 2026
Sheldon WhitehouseSenate / DPurchase$1.00K – $15.00KNov 21, 2025

Recently reported changes in GH holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by GH's directors and management

Net Shares Purchased by Insiders−5k−3k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

GH Estimated quarterly lobbying spending

Source: U.S. Senate LDA

GH Revenue by Segment or Geography

$360.98MTotal
Oncology$231.26M64.07%
Screening$67.61M18.73%
Biopharma and data$58.97M16.34%
Licensing and other$3.13M0.87%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New GH patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to GH from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in GH

VTIVanguard Morningstar Total Stock Market ETF$571.49M
VBVanguard Morningstar Small-Cap ETF$511.04M
VBKVanguard Morningstar Small-Cap Growth ETF$286.00M
VXFVanguard Extended Market ETF$272.11M
IWPiShares Russell Mid-Cap Growth ETF$94.07M
ARKGARK Genomic Revolution ETF$90.25M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from GH’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
9.59
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Product launch, raised guidance, and successful debt offering outweigh valuation concerns and insider selling.

Recent Insider Activity

Buys
0
Sells
9
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-35.0 since Aug 21
0255075100Aug 21 — Insider Score 35.0Aug 22 — Insider Score 35.0Aug 23 — Insider Score 35.0Aug 24 — Insider Score 35.0Aug 25 — Insider Score 35.0Aug 26 — Insider Score 35.0Aug 27 — Insider Score 35.0Aug 28 — Insider Score 35.0Aug 29 — Insider Score 35.0Aug 30 — Insider Score 35.0Aug 31 — Insider Score 35.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 31.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

HELXFranklin Genomic Advancements ETF8.63%
GNOMGlobal X - Genomics & Biotechnology ETF5.09%
LRNZTrueShares Technology, AI and Deep Learning ETF5.03%
ARKGARK Genomic Revolution ETF4.85%
HLTHTema Healthcare AI ETF4.60%
LFSCF/M Emerald Life Sciences Innovation ETF4.53%
SPITF/m Emerald Special Situations ETF3.75%
EKGFirst Trust Nasdaq Lux Digital Health Solutions ETF3.74%
CTAGCalamos Timpani Active SMID Growth ETF3.61%
MEDIHarbor Health Care ETF (MEDI)3.39%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF3.39%
PTHInvesco Dorsey Wright Healthcare Momentum ETF3.37%

Weight is the stock’s share of each fund’s holdings.